Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 4774-35-0 | MDL No. : | MFCD01632117 |
Formula : | C6H6N2O3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | KFWOVXLWAGKILN-UHFFFAOYSA-N |
M.W : | 154.12 | Pubchem ID : | 11744833 |
Synonyms : |
|
Num. heavy atoms : | 11 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.17 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 5.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 35.33 |
TPSA : | 72.31 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.83 cm/s |
Log Po/w (iLOGP) : | 1.22 |
Log Po/w (XLOGP3) : | 0.58 |
Log Po/w (WLOGP) : | -0.03 |
Log Po/w (MLOGP) : | -0.63 |
Log Po/w (SILICOS-IT) : | 0.26 |
Consensus Log Po/w : | 0.28 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.43 |
Solubility : | 5.69 mg/ml ; 0.0369 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.67 |
Solubility : | 3.28 mg/ml ; 0.0213 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -1.14 |
Solubility : | 11.2 mg/ml ; 0.0728 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.48 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
89% | Method of svnthesising A.25Sodium hydride (60 %; 1.40 g, 36.0 mmol) is placed in DMF (70 mL), mixed with carboxylic acid ester A.a.1 (5.00 g, 32.0 mmol) and stirred for 45 min at 20C. Then benzylbromide A.b.1 (4.10 mL, 32.0 mmol) is metered in and the mixture is stirred for a further 3 h at 20C. The reaction mixture is combined with HCI (50 mL, 1 N) and DCM (50 mL), the organic phase is separated off and extracted again with HCI (2 x 30 mL). Then the organic phase is dried, the solvent is eliminated in vacuo and carboxylic acid ester A*.25 (10.0 g, 89 %; HPLC-MS: MS(M+H)+ = 281 ; tRel = 1 .57 min; method FEC3) is obtained. | |
89% | Sodium hydride (60 %; 1.40 g, 36.0 mmol) is placed in DMF (70 mL), carboxylic acid ester A.a.1 (5.00 g, 32.0 mmol) is added and the mixture is stirred for 45 min at 20C. Then benzylbromide A.b.1 (4.10 mL, 32.0 mmol) is metered in and the mixture is stirred for a further 3 h at 20C. The reaction mixture is combined with HCI (50 mL, 1 N) and DCM (50 mL), the organic phase is separated off and extracted again with HCI (2 x 30 mL). Then the organic phase is dried, the solvent is eliminated in vacuo and carboxylic acid ester A*.32 (10.0 g, 89 %; HPLC-MS: MS(M+H)+ = 281 ; = 1.57 min; method FEC3) is obtained. | |
89% | Method of Synthesising A.25Sodium hydride (60%; 1.40 g, 36.0 mmol) is placed in DMF (70 mL), mixed with carboxylic acid ester A.a.1 (5.00 g, 32.0 mmol) and stirred for 45 min at 20 C. Then benzylbromide A.b.1 (4.10 mL, 32.0 mmol) is metered in and the mixture is stirred for a further 3 h at 20 C. The reaction mixture is combined with HCl (50 mL, 1 N) and DCM (50 mL), the organic phase is separated off and extracted again with HCl (2×30 mL). Then the organic phase is dried, the solvent is eliminated in vacuo and carboxylic acid ester A*.25 (10.0 g, 89%; HPLC-MS: MS (M+H)+=281; tRet.=1.57 min; method FEC3) is obtained.Carboxylic acid ester A*.25 (1.9 g, 5.6 mmol) is taken up in MeOH (7.3 mL) and mixed with NaOH (6.2 mL, 1 M). After 16 h at 20 C. the mixture is diluted with water and extracted with DCM. The organic phase is discarded, the aqueous phase is acidified and extracted with DCM. The organic phase is dried on Na2SO4, filtered, the solvent is eliminated in vacuo and the free carboxylic acid A.25 (694 mg, 47%; HPLC-MS: MS (M+H)+=267; tRet.=0.29 min; method FECB4) is obtained. |
a) Synthesis of free cyclic carboxylic acids A.1; Method for svnthesising A. Ia; Sodium hydride (60 %; 28.6 mg, 0.714 mmol) is suspended in 1.5 rnL DMF, combined with carboxylic acid ester B.l-la (100 mg, 0.649 mmol) and stirred for 45 min at 20C. Benzyl bromide B.2a (134 mg, 0.649 mmol) is metered into the suspension and it is stirred for a further 3 h at 200C. The reaction mixture is combined with 1 N hydrochloric acid and DCM, the organic phase is separated off and extracted 2 x with 1 N hydrochloric acid. Then the organic phase is dried, the solvent is eliminated in vacuo and carboxylic acid ester A.l*a (HPLC-MS: tRet. = 1.50 min; MS(M+H)+ = 281; method FECB3) is obtained. |
[ 15400-53-0 ]
Ethyl 2-amino-4-hydroxypyrimidine-5-carboxylate
Similarity: 0.86
[ 38324-83-3 ]
2-Hydroxypyrimidine-5-carboxylic acid
Similarity: 0.77
[ 397308-78-0 ]
4-Hydroxy-2-(methylthio)pyrimidine-5-carboxylic acid
Similarity: 0.74
[ 4786-53-2 ]
4-Hydroxypyrimidine-5-carboxamide
Similarity: 0.73
[ 20187-46-6 ]
Ethyl 4-amino-2-hydroxypyrimidine-5-carboxylate
Similarity: 0.73
[ 15400-53-0 ]
Ethyl 2-amino-4-hydroxypyrimidine-5-carboxylate
Similarity: 0.86
[ 15400-58-5 ]
Methyl 2,4-dimethoxypyrimidine-5-carboxylate
Similarity: 0.86
[ 308348-93-8 ]
Methyl 2-aminopyrimidine-5-carboxylate
Similarity: 0.81
[ 57401-76-0 ]
Ethyl 2-aminopyrimidine-5-carboxylate
Similarity: 0.78
[ 65195-35-9 ]
Ethyl 4-aminopyrimidine-5-carboxylate
Similarity: 0.78
[ 72411-89-3 ]
4-Methoxypyrimidine-5-carboxylic acid
Similarity: 0.97
[ 15400-53-0 ]
Ethyl 2-amino-4-hydroxypyrimidine-5-carboxylate
Similarity: 0.86
[ 15400-58-5 ]
Methyl 2,4-dimethoxypyrimidine-5-carboxylate
Similarity: 0.86
[ 23945-44-0 ]
2,4-Dihydroxypyrimidine-5-carboxylic acid
Similarity: 0.84